Ute Hamann - Genetic Mutations

Author Information

Ute Hamann is a prominent researcher affiliated with the Molecular Genetics of Breast Cancer department at the German Cancer Research Center (DKFZ) in Heidelberg, Germany. Her research primarily focuses on breast cancer genetics, particularly the role of BRCA1 and BRCA2 mutations in cancer susceptibility and risk prediction.

Research Contributions

Ute Hamann has made significant contributions to the field of breast cancer genetics. In 2022 alone, she authored numerous papers exploring various aspects of breast and ovarian cancer, such as the prevalence of BRCA1 and BRCA2 germline mutations, polygenic risk modeling for cancer prediction, and genome-wide interaction analyses. Her research has profound implications for understanding cancer risk and developing personalized medical strategies.

Aliases

Ute Hamann is also known by the aliases U Hamann and U. Hamann in various publications.

Publication and Citation Metrics

Metric	Value
Total Citation Count	29,233
H-Index	78
Paper Count	412

Publications:

Chasing the origin of 23 recurrent BRCA1 mutations in Pakistani breast and ovarian cancer patients.

DOI: 10.1002/ijc.34016

Year: 2022

Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk.

DOI: 10.1038/s41431-022-01085-y

Year: 2022

Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women

DOI: 10.1038/s41598-022-10121-2

Year: 2022

Prevalence of BRCA1 and BRCA2 Germline Mutations in Patients of African Descent with Early-Onset and Familial Colombian Breast Cancer

DOI: 10.1093/oncolo/oyab026

Year: 2022

Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes

DOI: 10.1001/jamaoncol.2021.6744

Year: 2022

Common variants in breast cancer risk loci predispose to distinct tumor subtypes

DOI: 10.1186/s13058-021-01484-x

Year: 2022

Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants.

DOI: 10.1200/JCO.21.02112

Year: 2022

Polygenic risk modeling for prediction of epithelial ovarian cancer risk

DOI: 10.1038/s41431-021-00987-7

Year: 2022

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

DOI: 10.1038/s41467-020-20496-3

Year: 2021

Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis

DOI: 10.1038/s41598-021-99409-3

Year: 2021

How is Hemophilia Diagnosed?

How are Patients Monitored During TKI Therapy?

How is Hemoglobin Electrophoresis Used in Clinical Practice?

What is Epigenetics?

What are the Options for Individuals with BRCA1 or BRCA2 Mutations?

What is Hemoglobin Electrophoresis?

What is the Prognosis for Individuals with Cystic Fibrosis?

What are Some Examples of Autosomal Recessive Disorders?

What is Mutation?

Can Mutations be Repaired?

Partnered Content Networks

Relevant Topics